NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Lemaitre Vascular Inc. LMAT
17 fiscal years on record · USD · FY2025 reported · SEC filings only
14 YEARS OF DIVIDEND GROWTH
In brief
What this company does
Written from the business description in LEMAITRE VASCULAR, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.
Growth
USD 249.6M
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2025 · Revenue 249.6 · Net income 57.7
Compound annual growth
+15.6%
+14.0%
+12.3%
+10.5%
+40.9%
+22.2%
+22.2%
+16.3%
+39.4%
+19.4%
+19.6%
+13.6%
+17.0%
+16.1%
+17.5%
+18.1%
+18.7%
+20.3%
+14.1%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +14.0% a year over five years — but profit grew faster: net income at +22.2%, earnings per share at +19.4%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
23 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 27.2% · Net 23.1%
ROE
FY2025 · ROE 15.8%
Each USD of equity produced 16 cents of profit this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Operating income $B | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA $B | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Net income $B | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow $B | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EPS, diluted $ | 2.52 | 1.93 | 1.34 | 0.93 | 1.25 | 1.04 | 0.88 | 1.13 | 0.86 | 0.55 | 0.42 | 0.23 | 0.20 | 0.16 | 0.13 | 0.37 | 0.10 |
| Dividend / sh $ | 0.80 | 0.64 | 0.56 | 0.50 | 0.44 | 0.38 | 0.34 | 0.28 | 0.22 | 0.18 | 0.16 | 0.14 | 0.12 | 0.10 | 0.08 | · | · |
| Payout % | 31 | 33 | 41 | 53 | 35 | 36 | 38 | 24 | 24 | 31 | 37 | 59 | 57 | 59 | 58 | · | · |
| ROE % | 15.8 | 13.9 | 10.6 | 7.9 | 12.6 | 13.2 | 12.9 | 19.1 | 17.4 | 12.8 | 10.6 | 6.3 | 5.9 | 4.9 | 4.1 | 12.0 | 3.3 |
| Shares out B | 0.02 | 0.02 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2009